Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC

Juergen C. Becker; Andreas Stang; Axel zur Hausen; Nicole Fischer; James A. DeCaprio; Richard W. Tothill; Rikke Lyngaa; Ulla Kring Hansen; Cathrin Ritter; Paul Nghiem; Christopher K. Bichakjian; Selma Ugurel; David Schrama

doi:10.1007/s00262-017-2099-3

Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC

Juergen C. Becker^*, Andreas Stang, Axel zur Hausen, Nicole Fischer, James A. DeCaprio, Richard W. Tothill, Rikke Lyngaa, Ulla Kring Hansen, Cathrin Ritter, Paul Nghiem, Christopher K. Bichakjian, Selma Ugurel, David Schrama

^*Corresponding author for this work

Research output: Contribution to journal › Journal article › Research › peer-review

173 Downloads (Orbit)

Abstract

Merkel cell carcinoma (MCC) is a highly aggressive, often lethal neuroendocrine cancer. Its carcinogenesis may be either caused by the clonal integration of the Merkel cell polyomavirus into the host genome or by UV-induced mutations. Notably, virally-encoded oncoproteins and UV-induced mutations affect comparable signaling pathways such as RB restriction of cell cycle progression or p53 inactivation. Despite its low incidence, MCC recently received much attention based on its exquisite immunogenicity and the resulting major success of immune modulating therapies. Here, we summarize current knowledge on epidemiology, biology and therapy of MCC as conclusion of the project 'Immune Modulating strategies for treatment of Merkel Cell Carcinoma', which was funded over a 5-year period by the European Commission to investigate innovative immunotherapies for MCC.

Original language	English
Journal	Cancer Immunology Immunotherapy
Volume	67
Issue number	3
Pages (from-to)	341-351
ISSN	0340-7004
DOIs	https://doi.org/10.1007/s00262-017-2099-3
Publication status	Published - 2018

Keywords

Cell of origin
Epidemiology
IMMOMEC
Immunotherapy
Merkel cell carcinoma
Merkel cell polyomavirus

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00262-017-2099-3

Nihms974454Accepted author manuscript, 1.32 MB

OpenUrl availability

Full text

Cite this

Becker, J. C., Stang, A., zur Hausen, A., Fischer, N., DeCaprio, J. A., Tothill, R. W., Lyngaa, R., Hansen, U. K., Ritter, C., Nghiem, P., Bichakjian, C. K., Ugurel, S., & Schrama, D. (2018). Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC. Cancer Immunology Immunotherapy, 67(3), 341-351. https://doi.org/10.1007/s00262-017-2099-3

@article{596bc2a8965c4eb5a9661320c536092b,

title = "Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC",

abstract = "Merkel cell carcinoma (MCC) is a highly aggressive, often lethal neuroendocrine cancer. Its carcinogenesis may be either caused by the clonal integration of the Merkel cell polyomavirus into the host genome or by UV-induced mutations. Notably, virally-encoded oncoproteins and UV-induced mutations affect comparable signaling pathways such as RB restriction of cell cycle progression or p53 inactivation. Despite its low incidence, MCC recently received much attention based on its exquisite immunogenicity and the resulting major success of immune modulating therapies. Here, we summarize current knowledge on epidemiology, biology and therapy of MCC as conclusion of the project 'Immune Modulating strategies for treatment of Merkel Cell Carcinoma', which was funded over a 5-year period by the European Commission to investigate innovative immunotherapies for MCC.",

keywords = "Cell of origin, Epidemiology, IMMOMEC, Immunotherapy, Merkel cell carcinoma, Merkel cell polyomavirus",

author = "Becker, {Juergen C.} and Andreas Stang and {zur Hausen}, Axel and Nicole Fischer and DeCaprio, {James A.} and Tothill, {Richard W.} and Rikke Lyngaa and Hansen, {Ulla Kring} and Cathrin Ritter and Paul Nghiem and Bichakjian, {Christopher K.} and Selma Ugurel and David Schrama",

year = "2018",

doi = "10.1007/s00262-017-2099-3",

language = "English",

volume = "67",

pages = "341--351",

journal = "Cancer Immunology Immunotherapy",

issn = "0340-7004",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "3",

}

Becker, JC, Stang, A, zur Hausen, A, Fischer, N, DeCaprio, JA, Tothill, RW, Lyngaa, R, Hansen, UK, Ritter, C, Nghiem, P, Bichakjian, CK, Ugurel, S & Schrama, D 2018, 'Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC', Cancer Immunology Immunotherapy, vol. 67, no. 3, pp. 341-351. https://doi.org/10.1007/s00262-017-2099-3

TY - JOUR

T1 - Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC

AU - Becker, Juergen C.

AU - Stang, Andreas

AU - zur Hausen, Axel

AU - Fischer, Nicole

AU - DeCaprio, James A.

AU - Tothill, Richard W.

AU - Lyngaa, Rikke

AU - Hansen, Ulla Kring

AU - Ritter, Cathrin

AU - Nghiem, Paul

AU - Bichakjian, Christopher K.

AU - Ugurel, Selma

AU - Schrama, David

PY - 2018

Y1 - 2018

N2 - Merkel cell carcinoma (MCC) is a highly aggressive, often lethal neuroendocrine cancer. Its carcinogenesis may be either caused by the clonal integration of the Merkel cell polyomavirus into the host genome or by UV-induced mutations. Notably, virally-encoded oncoproteins and UV-induced mutations affect comparable signaling pathways such as RB restriction of cell cycle progression or p53 inactivation. Despite its low incidence, MCC recently received much attention based on its exquisite immunogenicity and the resulting major success of immune modulating therapies. Here, we summarize current knowledge on epidemiology, biology and therapy of MCC as conclusion of the project 'Immune Modulating strategies for treatment of Merkel Cell Carcinoma', which was funded over a 5-year period by the European Commission to investigate innovative immunotherapies for MCC.

AB - Merkel cell carcinoma (MCC) is a highly aggressive, often lethal neuroendocrine cancer. Its carcinogenesis may be either caused by the clonal integration of the Merkel cell polyomavirus into the host genome or by UV-induced mutations. Notably, virally-encoded oncoproteins and UV-induced mutations affect comparable signaling pathways such as RB restriction of cell cycle progression or p53 inactivation. Despite its low incidence, MCC recently received much attention based on its exquisite immunogenicity and the resulting major success of immune modulating therapies. Here, we summarize current knowledge on epidemiology, biology and therapy of MCC as conclusion of the project 'Immune Modulating strategies for treatment of Merkel Cell Carcinoma', which was funded over a 5-year period by the European Commission to investigate innovative immunotherapies for MCC.

KW - Cell of origin

KW - Epidemiology

KW - IMMOMEC

KW - Immunotherapy

KW - Merkel cell carcinoma

KW - Merkel cell polyomavirus

U2 - 10.1007/s00262-017-2099-3

DO - 10.1007/s00262-017-2099-3

M3 - Journal article

C2 - 29188306

SN - 0340-7004

VL - 67

SP - 341

EP - 351

JO - Cancer Immunology Immunotherapy

JF - Cancer Immunology Immunotherapy

IS - 3

ER -

Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC

Abstract

Keywords

UN SDGs

Access to Document

OpenUrl availability

Fingerprint

Cite this